AstraZeneca: Liberum maintains 'buy' rating.
(CercleFinance.com) - Liberum maintains its "buy" rating on AstraZeneca shares, seeing upside potential, even after the failed Mystic trial for the treatment of lung cancer.
The brokerage firm thinks the shares are worth about 4,800 pence, assuming zero for Mystic, meaning upside potential of 8%.
While Mystic failed on progression-free survival (PFS), the trial could work at overall survival, the broker said, adding that in case of such an "unlikely but possible" favourable outcome, the shares would be worth another 300 to 1,000 pence per share.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The brokerage firm thinks the shares are worth about 4,800 pence, assuming zero for Mystic, meaning upside potential of 8%.
While Mystic failed on progression-free survival (PFS), the trial could work at overall survival, the broker said, adding that in case of such an "unlikely but possible" favourable outcome, the shares would be worth another 300 to 1,000 pence per share.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.